The EIB has signed a €12 million (DKK 89.3 million) loan agreement with Danish software company Templafy. The company is known for its platform that helps businesses better enable their business content, marrying their needs for compliance and productivity when creating business documents. Templafy will use the financing to further develop its business content solutions, and to drive the company’s successful expansion across Europe. The loan benefits from backing of the European Fund for Strategic Investments, main pillar of the Investment Plan for Europe.
The EIB has signed a €100 million (DKK 745 million) loan with Novozymes, the Danish-based world leader in biological solutions. The financing will support the company’s R&D investment plans for the coming years, and will mainly benefit R&D activities for discovering and producing enzymes that can be used in both industrial and home activities, reducing the need for traditional chemical products.
The EIB has signed a €20 million loan agreement with Evaxion, supported by the Infectious Diseases Finance Facility window under the EU’s InnovFin – EU finance for innovators programme, backed by the EU’s research and innovation programme Horizon 2020, which guarantees EIB loans for highly innovative projects. The financing will support Evaxion’s research and development (R&D) investments in the use of artificial intelligence (AI) to determine the most suitable targets for immunotherapies for cancer and infectious diseases.